196 related articles for article (PubMed ID: 10868279)
1. Transient host range selection for genetic engineering of modified vaccinia virus Ankara.
Staib C; Drexler I; Ohlmann M; Wintersperger S; Erfle V; Sutter G
Biotechniques; 2000 Jun; 28(6):1137-42, 1144-6, 1148. PubMed ID: 10868279
[TBL] [Abstract][Full Text] [Related]
2. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.
Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG
J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289
[TBL] [Abstract][Full Text] [Related]
3. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation.
Shisler JL; Jin XL
J Virol; 2004 Apr; 78(7):3553-60. PubMed ID: 15016878
[TBL] [Abstract][Full Text] [Related]
4. Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells.
Zwilling J; Sliva K; Schwantes A; Schnierle B; Sutter G
Virology; 2010 Sep; 404(2):231-9. PubMed ID: 20627347
[TBL] [Abstract][Full Text] [Related]
5. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant.
Sutter G; Ramsey-Ewing A; Rosales R; Moss B
J Virol; 1994 Jul; 68(7):4109-16. PubMed ID: 8207789
[TBL] [Abstract][Full Text] [Related]
6. Construction and isolation of recombinant MVA.
Staib C; Drexler I; Sutter G
Methods Mol Biol; 2004; 269():77-100. PubMed ID: 15114009
[TBL] [Abstract][Full Text] [Related]
7. Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection.
Wong YC; Lin LC; Melo-Silva CR; Smith SA; Tscharke DC
J Virol Methods; 2011 Jan; 171(1):295-8. PubMed ID: 21073901
[TBL] [Abstract][Full Text] [Related]
8. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.
Smith KA; Stallard V; Roos JM; Hart C; Cormier N; Cohen LK; Roberts BE; Payne LG
Vaccine; 1993; 11(1):43-53. PubMed ID: 8427036
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells.
Erez N; Wyatt LS; Americo JL; Xiao W; Moss B
J Virol; 2021 Sep; 95(19):e0110421. PubMed ID: 34232734
[TBL] [Abstract][Full Text] [Related]
10. High Frequency of Homologous Recombination in the Genome of Modified Vaccinia Virus Ankara Strain (MVA).
Zhu LX; Xie YH; Li GD; Wang Y
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2001; 33(5):497-503. PubMed ID: 12040389
[TBL] [Abstract][Full Text] [Related]
11. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.
Cottingham MG; Gilbert SC
J Virol Methods; 2010 Sep; 168(1-2):233-6. PubMed ID: 20417665
[TBL] [Abstract][Full Text] [Related]
12. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter G; Moss B
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10847-51. PubMed ID: 1438287
[TBL] [Abstract][Full Text] [Related]
13. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
Wyatt LS; Carroll MW; Czerny CP; Merchlinsky M; Sisler JR; Moss B
Virology; 1998 Nov; 251(2):334-42. PubMed ID: 9837798
[TBL] [Abstract][Full Text] [Related]
14. Notes on transient host range selection for engineering vaccinia virus strain MVA.
Tscharke DC; Smith GL
Biotechniques; 2002 Jul; 33(1):186-8. PubMed ID: 12139244
[No Abstract] [Full Text] [Related]
15. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.
Sutter G; Wyatt LS; Foley PL; Bennink JR; Moss B
Vaccine; 1994 Aug; 12(11):1032-40. PubMed ID: 7975844
[TBL] [Abstract][Full Text] [Related]
16. Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker.
Sánchez-Puig JM; Blasco R
Biotechniques; 2005 Nov; 39(5):665-6, 668, 670 passim. PubMed ID: 16312215
[TBL] [Abstract][Full Text] [Related]
17. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.
Hornemann S; Harlin O; Staib C; Kisling S; Erfle V; Kaspers B; Häcker G; Sutter G
J Virol; 2003 Aug; 77(15):8394-407. PubMed ID: 12857909
[TBL] [Abstract][Full Text] [Related]
18. [Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)].
Ferrer MF; Zanetti FA; Calamante G
Rev Argent Microbiol; 2007; 39(3):138-42. PubMed ID: 17987847
[TBL] [Abstract][Full Text] [Related]
19. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha.
Backes S; Sperling KM; Zwilling J; Gasteiger G; Ludwig H; Kremmer E; Schwantes A; Staib C; Sutter G
J Gen Virol; 2010 Feb; 91(Pt 2):470-82. PubMed ID: 19846675
[TBL] [Abstract][Full Text] [Related]
20. Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.
Peng C; Moss B
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3759-3767. PubMed ID: 32019881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
